Bavarian Nordic A/S (BVNRY)
OTCMKTS
· Delayed Price · Currency is USD
8.25
-0.01 (-0.06%)
May 12, 2025, 3:53 PM EDT
Bavarian Nordic Revenue
Bavarian Nordic had revenue of 1.35B DKK in the quarter ending March 31, 2025, with 61.95% growth. This brings the company's revenue in the last twelve months to 6.23B, down -6.18% year-over-year. In the year 2024, Bavarian Nordic had annual revenue of 5.72B, down -19.06%.
Revenue (ttm)
6.23B DKK
Revenue Growth
-6.18%
P/S Ratio
2.14
Revenue / Employee
3.88M DKK
Employees
1,605
Market Cap
1.93B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.72B | -1.35B | -19.06% |
Dec 31, 2023 | 7.06B | 3.91B | 124.14% |
Dec 31, 2022 | 3.15B | 1.25B | 66.02% |
Dec 31, 2021 | 1.90B | 45.49M | 2.46% |
Dec 31, 2020 | 1.85B | 1.19B | 179.61% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Bavarian Nordic News
- 3 days ago - Bavarian Nordic A/S (BVNKF) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such - GlobeNewsWire
- 3 days ago - Bavarian Nordic A/S 2025 Q1 - Results - Earnings Call Presentation - Seeking Alpha
- 4 days ago - Bavarian Nordic A/S reports interim Q1 results - Seeking Alpha
- 4 days ago - Bavarian Nordic Announces Interim Results for the First Three Months of 2025 - GlobeNewsWire
- 7 days ago - Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines - GlobeNewsWire
- 11 days ago - Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom - GlobeNewsWire
- 26 days ago - Bavarian Nordic's Chikungunya Vaccine Receives Recommendation from U.S. CDC's Advisory Committee on Immunization Practices (ACIP) - GlobeNewsWire